Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: sds who wrote (1349)	12/3/1997 7:24:00 PM
From: Rob J	Respond to of 4676

I suspect your right on ISIS-2292. I am looking for reasons not to pull the trigger on ISIP for year-end tax losses. Hoping Stanley Crook's presentation at NIH tomarrow or Lisa Grillone's presentation presentation on ISIS-2292 in San Fransisco on Dec. 8 & 9 will be a positive events. Anyone have any opinions on that. Here are some upcoming company presentations. Stanley T. Crooke, M.D., Ph.D. - Founder, Chairman and CEO o December 5, 1997 - 2nd NIH Symposium, Bethesda, Maryland - Therapeutic Oligo Targeting Translation Factors" o December 10-11, 1997 - Global Business Research - Financing and Strategic Alliances for Emerging & Established Genomic Companies, San Diego, CA - Keynote Speaker "Genomics: Past Present & Future". For information visit their website at www.global8.com. Lisa Grillone, Director, Drug Development o December 8-9, 1997 -- Institute for International Research, San Francisco, CA -- "Clinical Development of ISIS 2922" for information call 800-999-3123. Greg Hardee, Ph.D., Director, Drug Development Research and Pharmaceutical Development: Dec. 11 + 12, 1997 at 2:15, IBC's Conference on Gene Therapy in La Jolla. "Antisense Oligonucleotides: Delivery and Distribution" Dec. 17 + 18, 1997 at 3:15, IBC's "Delivery of Proteins, Peptides and Nucleic Acids" conference at the Hotel Del Coronado. "Antisense Oligonucleotides: Delivery and Distribution"